Clinical Trial Update: Safety and Efficacy of Asacol 4.8 g/Day Versus Asacol 2.4 g/Day (ASCEND I) [Phase 3]

View source ↗

Summary

Phase 3 ASCEND I trial comparing high-dose (4.8 g/day) versus standard-dose (2.4 g/day) mesalamine (Asacol) in ulcerative colitis; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Asacol (mesalamine)

Snippet

Sponsor: Warner Chilcott | Conditions: Ulcerative Colitis | Phase 3 | Status: COMPLETED | Results posted: 2011-06-22